Chunying Hou

432 total citations
19 papers, 314 citations indexed

About

Chunying Hou is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Chunying Hou has authored 19 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Chunying Hou's work include MicroRNA in disease regulation (3 papers), Cancer Cells and Metastasis (3 papers) and Peptidase Inhibition and Analysis (3 papers). Chunying Hou is often cited by papers focused on MicroRNA in disease regulation (3 papers), Cancer Cells and Metastasis (3 papers) and Peptidase Inhibition and Analysis (3 papers). Chunying Hou collaborates with scholars based in China and Canada. Chunying Hou's co-authors include Y Liu, Pingping Zuo, Yao Jiang, Ji Zheng, Dongqing Guo, Tianhua Liu, Bo Sun, Nan Yang, Mengmeng Lin and Chao Ji and has published in prestigious journals such as Journal of Controlled Release, International Journal of Pharmaceutics and Biomedicine & Pharmacotherapy.

In The Last Decade

Chunying Hou

18 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chunying Hou China 12 191 86 82 52 39 19 314
Huimei Yi China 8 191 1.0× 79 0.9× 95 1.2× 48 0.9× 52 1.3× 8 365
Chao Feng China 12 252 1.3× 90 1.0× 96 1.2× 22 0.4× 39 1.0× 27 413
Andrea L. Merz United States 11 195 1.0× 115 1.3× 62 0.8× 47 0.9× 30 0.8× 14 381
Mahdieh Razmi Iran 12 170 0.9× 112 1.3× 44 0.5× 34 0.7× 23 0.6× 21 352
Negar Azami Iran 6 302 1.6× 49 0.6× 139 1.7× 95 1.8× 69 1.8× 6 464
Laura Bender France 10 164 0.9× 105 1.2× 43 0.5× 37 0.7× 47 1.2× 33 451
Liwen Li China 11 230 1.2× 48 0.6× 57 0.7× 35 0.7× 27 0.7× 21 398
Yuxin Zhuang China 12 182 1.0× 55 0.6× 81 1.0× 25 0.5× 40 1.0× 26 393
Scott L. Young United States 4 222 1.2× 109 1.3× 74 0.9× 22 0.4× 29 0.7× 6 425

Countries citing papers authored by Chunying Hou

Since Specialization
Citations

This map shows the geographic impact of Chunying Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunying Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunying Hou more than expected).

Fields of papers citing papers by Chunying Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunying Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunying Hou. The network helps show where Chunying Hou may publish in the future.

Co-authorship network of co-authors of Chunying Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Chunying Hou. A scholar is included among the top collaborators of Chunying Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunying Hou. Chunying Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lv, Xinyi, Tianhua Liu, Qingqing Wang, et al.. (2025). Ginsenoside Rg3 Adjunctively Increases the Efficacy of Gefitinib Against NSCLC by Regulating EGFR Copy Number. Pharmaceuticals. 18(7). 1077–1077.
2.
Li, Yingying, Shiyuan Wang, Mengmeng Lin, et al.. (2022). Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Frontiers of Medicine. 16(3). 307–321. 12 indexed citations
3.
Lin, Mengmeng, Weiping Xiong, Shiyuan Wang, et al.. (2022). The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment. Frontiers in Cardiovascular Medicine. 8. 821663–821663. 39 indexed citations
4.
Xu, Ran, Tianhua Liu, Ling Zuo, et al.. (2021). The high expression of miR-31 in lung adenocarcinoma inhibits the malignancy of lung adenocarcinoma tumor stem cells. Biochemistry and Biophysics Reports. 28. 101122–101122. 4 indexed citations
5.
Lin, Dayu, Shuai Li, Chunying Hou, et al.. (2021). Exploring the biological mechanism of qi deficiency syndrome with chronic obstructive pulmonary disease (COPD) based on integrated pharmacology. Journal of Traditional Chinese Medical Sciences. 8(1). 72–81. 4 indexed citations
6.
Hou, Chunying, et al.. (2020). TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomedicine & Pharmacotherapy. 126. 109862–109862. 21 indexed citations
7.
Liu, Tianhua, Ling Zuo, Dongqing Guo, et al.. (2019). Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomedicine & Pharmacotherapy. 120. 109483–109483. 50 indexed citations
8.
Liu, Tianhua, Jian Guo, Tongxin Wang, et al.. (2019). Network pharmacology-based analysis of mechanisms of the anti-hepatocellular carcinoma effect by dihydroartemisinin.. Discovery Medicine. 28(153). 139–147. 4 indexed citations
9.
Zhang, Hewei, Shuran Ma, Ya Xu, et al.. (2018). Inhibitory effect of Sumu (Lignum Sappan) plus Fuzi (Radix Aconiti Lateralis Praeparata) on a lung carcinoma model. Journal of Traditional Chinese Medicine. 38(2). 211–217. 3 indexed citations
11.
Zhang, Shiqian, Chunying Hou, Guojun Li, et al.. (2016). A single nucleotide polymorphism in the 3′-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells. International Journal of Molecular Medicine. 38(3). 919–926. 12 indexed citations
12.
Hou, Chunying, Bo Sun, Yao Jiang, et al.. (2016). MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry. 16(4). 501–518. 20 indexed citations
13.
Jiang, Yao, Nan Yang, Huifeng Zhang, et al.. (2015). Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. Journal of Controlled Release. 221. 26–36. 33 indexed citations
14.
Liang, Zhen, Nan Yang, Yao Jiang, et al.. (2015). Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer. International Journal of Pharmaceutics. 494(1). 337–345. 18 indexed citations
15.
Sun, Bo, Nan Yang, Yao Jiang, et al.. (2015). Antagomir-1290 suppresses CD133+ cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase. Tumor Biology. 36(8). 6223–6230. 17 indexed citations
16.
Zhang, Rui, Nan Yang, Chao Ji, et al.. (2015). Neuroprotective effects of Aceglutamide on motor function in a rat model of cerebral ischemia and reperfusion. Restorative Neurology and Neuroscience. 33(5). 741–759. 21 indexed citations
17.
Yang, Nan, Yao Jiang, Huifeng Zhang, et al.. (2014). Active Targeting Docetaxel-PLA Nanoparticles Eradicate Circulating Lung Cancer Stem-like Cells and Inhibit Liver Metastasis. Molecular Pharmaceutics. 12(1). 232–239. 31 indexed citations
18.
Yang, Nan, Beichen Sun, Yao Jiang, et al.. (2013). CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential. Neoplasma. 61(2). 153–160. 18 indexed citations
19.
Liu, Huiping, Zu‐Hua Gao, Shu‐Xiang Cui, et al.. (2011). Haishengsu, a Protein from Shellfish Tegillarca L. granosa, Inhibits the Growth and the Activity of Matrix Metalloproteinases-2 and -9 in Human Lung Carcinoma. Food Biophysics. 6(3). 390–396. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026